This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.
a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. F.A.C.C.
a leader in AI-driven healthcare technology, announced the launch of the DECIDE Registry, the largest prospective registry of its kind, with the first site initiated, Cone Health Care. 2 “Data from the DECODE study shows the value of using Plaque Analysis. 2 “Data from the DECODE study shows the value of using Plaque Analysis.
The CaRi-Plaquetechnology supports non-invasive analysis of coronary anatomy and pathology from routine coronary computed tomography angiography (CCTA) scans to determine the presence, extent and severity of coronary plaques and luminal stenosis (narrowing of arteries). But with AI, we can change that.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. The CaRi-Heart technology is in clinical use in the UK, European Union, and Australia.
a provider of AI technology for coronary artery disease (CAD) management, recently introduced its new brand identity reflecting its focus on delivering clarity, precision and confidence in the prevention, diagnosisand treatment of CAD. tim.hodson Wed, 02/26/2025 - 10:24 Feb. 25, 2025 Heartflow, Inc. , In the U.S.,
The company’s advanced non-invasive computed tomography (CT) imaging technology enables comprehensive phenotyping of coronary artery disease, grounded in scientific research based on millions of medical images. Until Cleerly, healthcare providers have had no way to easily and completely assess plaque burden in a non-invasive manner.
a leader in non-invasive artificial intelligence (AI) heart care solutions, announced that the data from its REVEALPLAQUE study , highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal Cardiovascular Imaging. milla1cf Thu, 05/23/2024 - 08:00 May 23, 2024 — HeartFlow, Inc. ,
This registry will aim to provide world-wide physicians the most accurate information on coronary plaque to improve cardiovascular risk prediction and support the selection of patient-specific treatment,” said Dr. De Cecco. Márton Kolossváry (Gottsegen National Cardiovascular Center, Budapest, Hungary).
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. This restores the vessel viability and hemodynamic modulation by returning pulsatility, compliance, adaptive blood flow volume, and plaque stabilization and regression.
15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.
a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ).
mm (green outline) section thickness show the respective calcified plaque (arrowheads) and coronary stenosis (inset images). The technology has the potential to improve patient management and reduce unnecessary interventions. No substantial benefits of ultrahigh-spatial-resolution were observed for mixed and non-calcified plaques. “It
Developing and driving clinical evidence is crucial to improving care and guiding the adoption of new technologies like the Philips laser atherectomy and lithotripsy system,” said Drs. The care team there successfully treated a 78-year-old male with peripheral vascular disease using the Philips device.
The Neuroguard Integrated Embolic Protection (IEP) system is an experimental treatment for carotid artery stenosis, also known as carotid artery disease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck. Designed by Raleigh, N.C.
ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. Following Breakthrough Device Designation granted for the technology by the FDA in 2021, the approval was supported by positive results from the multicenter, prospective, randomized controlled AGENT IDE trial , which enrolled 600 patients at 40 U.S.
Specific genetic variants, such as those affecting cholesterol metabolism, can increase the likelihood of plaque buildup in the arteries. Gene-based therapies and interventions, such as gene editing technologies, show potential in treating hereditary conditions, although these treatments are still in early stages.
30, 2024 — HeartLung Technologies , a developer of AI tools for early detection of heart disease, lung cancer and other conditions announced that its AI-enabled Automated Cardiac Chambers Volumetry (AutoChamber) recently received “Breakthrough Medical Device” designation and marketing authorization from the U.S. “By
Better reimbursement for hospitals leads to improved accessibility to this technology, which is a win for everyone involved, most notably patients.” HeartFlow remains dedicated to reshaping cardiovascular care and ensuring that hospitals have access to comprehensive, accurate, and efficient solutions in precision coronary care.
Improved patient safety with reduced radiation and contrast load Enhancing patient safety is a pivotal aspect of advanced cardiac imaging technology. By employing advanced scanning technology, healthcare providers can ensure patients undergo diagnostic procedures with minimized risks.
In many cases, plaque preparation is a critical prerequisite for delivery of devices across calcific stenoses and also to achieve adequate luminal dimensions. Recent advances in intracoronary imaging and adjunctive technologies now allow the operator to select the most appropriate strategy in each individual case.
tim.hodson Tue, 10/01/2024 - 10:50 PHOTO CAPTION: The Elucid PlaqueIQ user interface is a fully interactive visualization of the patient’s coronary anatomy, showing specific plaque type and amount across various views to inform physician assessment of risk and patient-specific treatment pathway.
The mechanisms by which ICAD causes stroke include plaque rupture with in situ thrombosis and occlusion or artery-to-artery embolization, hemodynamic injury, and branch occlusive disease. In fact, the 1-year recurrent stroke rate of >20% among those with stenosis >70% is one of the highest rates among common causes of stroke.
2-4 HeartFlow’s non-invasive FFR CT technology has emerged as a leading frontline strategy for accurately diagnosing hemodynamically significant coronary lesions in patients suspected of having CAD. 5 Revascularization to improve blood flow to the heart has been shown to reduce mortality in stable chest pain patients.
7 While HeartFlow was founded with FFR CT technology, the company has evolved from a single product used to assess the impact that narrowing vessels have on coronary blood flow (FFR CT Analysis), to a comprehensive suite of non-invasive technologies that build on CCTA. said John Farquhar, Chief Executive Officer at HeartFlow.
According to the company, Earls is a leader within the field of radiology and specializes in applications of advanced imaging technologies in cardiovascular care. He is the author of over 150 articles, book chapters, abstracts and other publications on advanced imaging technologies. With Plaque Features Associated with False Positives.
Zixiao Li added, “This type of technology aids neurologists by facilitating the sharing of information between humans and AI, using their combined strengths.” 87% of strokes are ischemic strokes, which occur when blood vessels to the brain become narrowed or clogged with plaque, cutting off blood flow to the brain. In the U.S.,
For PAD, the clot-sensing technology is being developed to instantly identify fresh clot and differentiate it from organized clot thrombus poor in RBCs as well as plaque, calcium and other tissue in real-time to inform individualized PAD treatment. we aspirate, dissolve the clot, or use another method?
Historically, the radiation required to perform CTCA scans was relatively high, but with the advent of newer scanning technologies, that dose has been significantly reduced 1. A CTCA provides much more anatomical detail and can identify advanced plaque often missed by CT Coronary Artery Calcium Score scans alone.
As technologies advance and methodologies evolve, two crucial tools stand out for their pivotal roles in enhancing accuracy and efficacy: Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS). OCT employs light waves to capture high-resolution images, providing intricate details of vessel structures and plaque composition.
Irradiation of 282 nm UV‐B but not 301 or 312 nm UV‐B significantly reduced the development of aortic root atherosclerotic plaques and plaque inflammation.
Natural compound libraries were screened to identify potent METTL4 antagonists. Pemetrexed was identified as the first METTL4 antagonist to effectively alleviate atherosclerotic progression.
At the forefront of this quest lie the remarkable advancements in imaging technology, ushering in a new era of precision and insight. Cutting-edge Computed Tomography (CT) and Cardiac MRI technologies are transforming this domain, offering unprecedented insights into the intricate workings of the heart and vascular system.
At the forefront of this quest lie the remarkable advancements in imaging technology, ushering in a new era of precision and insight. Cutting-edge Computed Tomography (CT) and Cardiac MRI technologies are transforming this domain, offering unprecedented insights into the intricate workings of the heart and vascular system.
Why IVUS and OCT Are Vital These technologies aren't just extras; they are the ticket to enhanced diagnostic accuracy and improved patient results. IVUS reveals plaque characteristics, optimal stent usage, and vessel measurements. Meanwhile, OCT employs light waves to capture tiny vessel wall details.
As technologies advance and methodologies evolve, two crucial tools stand out for their pivotal roles in enhancing accuracy and efficacy: Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS). OCT employs light waves to capture high-resolution images, providing intricate details of vessel structures and plaque composition.
eGC shedding could contribute to atherosclerotic plaque vulnerability and acute myocardial infarction (AMI) installation. The integrity of this structure sustains some vascular properties such as shear stress-induced nitric oxide release and the prevention of platelets and neutrophils adhesion on the vessel surface.
Heartflow is a proprietary technology that purports to evaluate the presence of significant narrowing in the coronary arteries just by doing a heart CT scan. To make matters even more complicated, plaque in younger patients may be non-calcified and invisible to CT-calcium scans.
ET Main Tent (Hall B1) A Selective Aldose Reductase Inhibitor (at-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results of IMPROVE-HCM Topical (..)
Clinical and Investigative Horizons The Clinical and Investigative Horizons is a new type of late-breaker session that was added for ACC23 and is back by popular demand.
Technological advancements have revolutionized the medical industry; now, portable ECG devices are also available. Coronary artery disease Excessive cholesterol builds up plaque that blocks the arteries supplying blood to the heart. Lead wires connect these patches to the ECG machine. This condition is also called atherosclerosis.
She was treated medically for NonSTEMI, pending next day cath, which showed ulcerated plaque and a 60% thrombotic stenosis in the LAD distal to the first diagonal. Wall motion abnormalities are very hard to see, even with advanced Speckle Tracking technology. Regional wall motion abnormality-distal septum and apex. It was stented.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content